Loading stock data…
Supernus Pharmaceuticals, Inc. (SUPN)
$46.51-0.29 (-0.62%)
Market ClosedLast close Jun 30
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Supernus Pharmaceuticals, Inc. in the Healthcare sector is trading at $46.51 with a market capitalization of $2.6B. Wall Street consensus targets $62.83 (6 analysts), implying a +35.1% move over the next 12 months. The stock is currently 22% below its 52-week high of $59.68, remaining 5.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +35.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $207.71M↓ | $211.57M↑ | $192.10M↑ | $165.45M↑ | $149.82M |
| Gross Profit | $184.31M↓ | $188.56M↑ | $173.14M↑ | $148.63M↑ | $134.06M |
| Operating Income | -$5.94M↓ | $13.82M↑ | -$60.23M↓ | $12.14M↑ | -$2.60M |
| Net Income | -$2.29M↑ | -$4.11M↑ | -$45.12M↓ | $22.50M↑ | -$11.83M |
Peer Comparison
JNJUNHPFE
Fundamentals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated fo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.69%
Volume
Today's trading volume
679,966
Recent News
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers.
3 of Wall Street’s Favorite Stocks We Approach with Caution
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500’s 9.3% gain. This might have investors contemplating their next move.
1 Cash-Heavy Stock on Our Watchlist and 2 Facing Challenges
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate
Supernus Pharmaceuticals triggered Milestone 1 under its Contingent Value Rights Agreement, resulting in a significant cash payment obligation to CVR holders. The milestone achievement represents a material corporate event tied to the company’s progress on defined objectives. The current share price of NasdaqGM:SUPN is $48.21 at the last close. For investors watching NasdaqGM:SUPN, this CVR milestone comes after a period of mixed share performance, with the stock up 50.2% over the past year...